Business Summary

Living Cell Technologies is engaged in the clinical development of cell based therapeutics for the treatment of diabetes and pre-clinical research and development into neurological disorders predominantly in New Zealand. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. The Company's lead product, DIABECELL®, consists of microencapsulated porcine islets which are implanted into a patient's abdomen using a simple laparoscopic procedure.   

Data provided by Mergent, Inc.

Recent Company News

Powered by Interactive Data Managed Solutions

Recent / Upcoming DR Events

Data provided by Thomson Reuters, Inc.
DR Symbol LVCLY
CUSIP 53838R107
DR Exchange OTCQX
DR ISIN US53838R1077
Ratio DR:ORD 1:10
Depositary BK (Sponsored)
Effective Date Jul 17, 2007
Underlying ISIN AU000000LCT6
Underlying SEDOL B01S530
Country Australia
Industry Pharma. & Biotech.

Powered by Interactive Data Managed Solutions

Monthly DR Trading Summary

Month Month End
DR Close
Price		 DR Trading Volume Avg Day DR
Trading
Volume
May. 13 0.44 128,845 8,053
Apr. 13 0.43 480,774 22,894
Mar. 13 0.50 194,743 11,455
Data provided by Interactive Data Corp.

This DR is a Constituent of the following BNY Mellon DR Indices:

Classic ADR Index

Related links

Custodians / BIC

Helpful Links
This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

© 2013 The Bank of New York Mellon Corporation. Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Quotes delayed at least 15 minutes.Market data provided by Interactive Data
Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.

Certain information included in this website is proprietary to Mergent, Inc. (Mergent) Copyright © 2003-2010. Reproduction of such information in any form is prohibited. Because of the possibility of
human or mechanical error by Mergent's sources, Mergent or others, Mergent does not guarantee the accuracy, adequacy, completeness, timeliness or availability or for the results obtained from the
use of such information. Mergent Terms of Use apply

Holdings information provided by FactSet Research Systems Inc. Copyright © 2003-2013 FactSet Research Systems Inc. All rights reserved.

DR Calendar provided by Thomson Reuters, Inc. © 2013 The Thomson Reuters Corporation. All Rights Reserved. Terms of Use. Privacy Statement.
Send questions, comments or suggestions to corporateservices@thomsonreuters.com